Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 12/20 | 0.44 |
| ▸ | ACACA | Q13085 | 8/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21341632 | 0.90 | ACACB (0.46) | ACACBACACAPLA2G4BHPGDLMNA | |
| SCHEMBL21906681 | 0.87 | ACACB (0.40) | ACACBACACAHPGDLMNA | |
| SCHEMBL20372470 | 0.86 | ACACB (0.46) | ACACBACACAPLA2G4BHPGDLMNA | |
| SCHEMBL24788112 | 0.85 | ACACB (0.46) | ACACBACACAPLA2G4BHPGDLMNA | |
| SCHEMBL21214833 | 0.82 | PLA2G4B (0.44) | ACACBPLA2G4B | |
| SCHEMBL23350266 | 0.82 | PLA2G4B (0.44) | ACACBPLA2G4B | |
| SCHEMBL20325827 | 0.78 | ACACB (0.44) | ACACBACACAHPGDLMNA | |
| SCHEMBL21664495 | 0.78 | PLA2G4B (0.44) | ACACBPLA2G4BLMNA | |
| SCHEMBL21025837 | 0.77 | MEN1 (0.39) | ACACBACACAPLA2G4B | |
| SCHEMBL21025856 | 0.77 | PLA2G4B (0.37) | PLA2G4BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | ACACB 3411/4885ACACA 3181/4885PLA2G4B 2402/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | ACACB 3411/4885ACACA 3181/4885PLA2G4B 2402/4885 |
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | ACACB 2080/4885ACACA 2089/4885PLA2G4B 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.